Ruolin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruolin Li has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Medina-Gomez
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
4 shared publications - Fernando Rivadeneira
Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
2 shared publications Robert Kraaij
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications- Alejandro Lopez-Rincon
Utrecht University, Utrecht, Netherlands
1 shared publication Alexander Kurilshikov
Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands
1 shared publicationAlexandra Zhernakova
Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
The association of gut microbiome composition with musculoskeletal features in middle-aged and older adults: a two-cohort joint study
Background: Bones and muscles are connected anatomically, and functionally. Preliminary evidence has shown the gut microbiome influences the aging process of bone and muscle in animal studies. However, such evidence in humans is still scarce. This study aimed to assess the microbiome-bone and microbiome-muscle associations in two cohorts of community-dwelling older adults. Methods: We leveraged information from two large population-based cohorts, i.e., the Rotterdam Study (mean age 62.7 ± 5.6 years; n=1,249) and the Framingham Heart Study (mean age 55.2 ± 9.1 years; n=1,227). For individuals included in this study, gut microbiome 16S rRNA sequencing, musculoskeletal phenotyping derived from DXA images, lifestyle and socioeconomic data, and medication records were available. Per cohort, the 16S rRNA sequencing data, derived from stool, were processed with the DADA2 pipeline and taxonomies were assigned using the SILVA reference database. In addition, the microbiome functional potential was obtained with PICRUSt2. Further, we investigated the association between the human gut microbiome (alpha diversity, genera and predicted functional pathways) and appendicular lean mass (ALM), femoral neck bone mineral density (FN-BMD) and trabecular bone score (TBS) using multilinear regression models controlling for multiple confounders, and performed a joint analysis from both cohorts. Sex-stratified analyses were also conducted. Results: The gut microbiome alpha diversity was not associated with either tested phenotype after accounting for multiple-testing (P>1.67e-02). In the joint analysis, lower abundance of Oscillibacter (beta= −.51, 95%CI [−0.74, −.29]), Anaerotruncus (beta=-0.41, 95%CI [−0.61, - 0.21]), Eisenbergiella (beta=-0.39, 95%CI [−0.59, −.19]) and higher abundance of Agathobacter (beta=0.40, 95%CI [0.20, 0.60]) were associated with higher ALM (PAnaerotruncus (beta=-0.32, 95%CI [−0.45, −.19]), Hungatella (beta=-0.26, 95%CI [−0.38, −.15]) and Clostridiales bacterium DTU089 (beta=-0.37, 95%CI [−0.55, −.19]) was associated with higher ALM only in females (P< 2.0e-04). Moreover, the biotin biosynthesis II pathway was positively associated with ALM (beta=0.44, 95% CI [0.24, 0.64]) (P<1.90e-04) in females while no associations were observed in males. We did not observe any robust association of bone traits with gut microbiome features. Conclusion: Our results indicate that specific genera are associated with ALM in middle-aged and older adults and these associations can present in a sex-specific manner. Overall, our study suggests that the gut microbiome is linked to muscle aging in middle-aged and older adults. However, larger sample sizes are still needed to underpin the specific microbiome features involved.
Open AccessThe association of gut microbiome composition with musculoskeletal features in middle-aged and older adults: a two-cohort joint study
Background: Bones and muscles are connected anatomically, and functionally. Preliminary evidence has shown the gut microbiome influences the aging process of bone and muscle in animal studies. However, such evidence in humans is still scarce. This study aimed to assess the microbiome-bone and microbiome-muscle associations in two cohorts of community-dwelling older adults. Methods: We leveraged information from two large population-based cohorts, i.e., the Rotterdam Study (mean age 62.7 ± 5.6 years; n=1,249) and the Framingham Heart Study (mean age 55.2 ± 9.1 years; n=1,227). For individuals included in this study, gut microbiome 16S rRNA sequencing, musculoskeletal phenotyping derived from DXA images, lifestyle and socioeconomic data, and medication records were available. Per cohort, the 16S rRNA sequencing data, derived from stool, were processed with the DADA2 pipeline and taxonomies were assigned using the SILVA reference database. In addition, the microbiome functional potential was obtained with PICRUSt2. Further, we investigated the association between the human gut microbiome (alpha diversity, genera and predicted functional pathways) and appendicular lean mass (ALM), femoral neck bone mineral density (FN-BMD) and trabecular bone score (TBS) using multilinear regression models controlling for multiple confounders, and performed a joint analysis from both cohorts. Sex-stratified analyses were also conducted. Results: The gut microbiome alpha diversity was not associated with either tested phenotype after accounting for multiple-testing (P>1.67e-02). In the joint analysis, lower abundance of Oscillibacter (beta= −.51, 95%CI [−0.74, −.29]), Anaerotruncus (beta=-0.41, 95%CI [−0.61, - 0.21]), Eisenbergiella (beta=-0.39, 95%CI [−0.59, −.19]) and higher abundance of Agathobacter (beta=0.40, 95%CI [0.20, 0.60]) were associated with higher ALM (PAnaerotruncus (beta=-0.32, 95%CI [−0.45, −.19]), Hungatella (beta=-0.26, 95%CI [−0.38, −.15]) and Clostridiales bacterium DTU089 (beta=-0.37, 95%CI [−0.55, −.19]) was associated with higher ALM only in females (P< 2.0e-04). Moreover, the biotin biosynthesis II pathway was positively associated with ALM (beta=0.44, 95% CI [0.24, 0.64]) (P<1.90e-04) in females while no associations were observed in males. We did not observe any robust association of bone traits with gut microbiome features. Conclusion: Our results indicate that specific genera are associated with ALM in middle-aged and older adults and these associations can present in a sex-specific manner. Overall, our study suggests that the gut microbiome is linked to muscle aging in middle-aged and older adults. However, larger sample sizes are still needed to underpin the specific microbiome features involved.
- Open Access
A comprehensive quality control pipeline in human microbiome research for large population studies
: The widespread application of high-throughput Next Generation Sequencing (NGS) technologies has made microbiome research an emerging field in public health and biomedical sciences. However, there are still many challenges that need to be addressed in this field. Pipelines available to generate microbiome data across cohorts are diverse, and sources of variation to be recorded and evaluated during microbiome profiling have not been standardized. Moreover, meticulous quality control of the microbiome data processing, from collection to computational quantification is still challenging, especially in large population studies. Innovative approaches are required to handle samples and to minimize the potential bias introduced by logistic hurdles in biobanking. In this paper, we describe the methodological steps surrounding the optimization of the 16s rRNA gut microbiome profiling in two large prospective cohorts the Generation R Study (mean age 9.83 ± 0.32 years) and the Rotterdam Study (mean age 62.67 ± 5.66 years). This paper also highlights potential solutions to sample mislabeling in large-scale microbiome analysis. To summarize, our study addresses common problems in human microbiome research. It aims to improve the research quality and reliability by integrating more stringent quality control standards into microbiome research.
Open AccessA comprehensive quality control pipeline in human microbiome research for large population studies
: The widespread application of high-throughput Next Generation Sequencing (NGS) technologies has made microbiome research an emerging field in public health and biomedical sciences. However, there are still many challenges that need to be addressed in this field. Pipelines available to generate microbiome data across cohorts are diverse, and sources of variation to be recorded and evaluated during microbiome profiling have not been standardized. Moreover, meticulous quality control of the microbiome data processing, from collection to computational quantification is still challenging, especially in large population studies. Innovative approaches are required to handle samples and to minimize the potential bias introduced by logistic hurdles in biobanking. In this paper, we describe the methodological steps surrounding the optimization of the 16s rRNA gut microbiome profiling in two large prospective cohorts the Generation R Study (mean age 9.83 ± 0.32 years) and the Rotterdam Study (mean age 62.67 ± 5.66 years). This paper also highlights potential solutions to sample mislabeling in large-scale microbiome analysis. To summarize, our study addresses common problems in human microbiome research. It aims to improve the research quality and reliability by integrating more stringent quality control standards into microbiome research.
- Open Access
- 27 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 50, 101195
Association between gut microbiome profiles and host metabolic health across the life course: a population-based study
- 27 December 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 50, 101195
Open AccessAssociation between gut microbiome profiles and host metabolic health across the life course: a population-based study
- Open Access
Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.
Open AccessBi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.